We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers in Patients With Head and Neck Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01466257
First Posted: November 7, 2011
Last Update Posted: May 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )
November 2, 2011
November 7, 2011
May 19, 2017
November 21, 2011
January 1, 2012   (Final data collection date for primary outcome measure)
Mutation rates of HRAS and PIK3CA [ Time Frame: 1 day ]
Mutation rates of HRAS and PIK3CA
Complete list of historical versions of study NCT01466257 on ClinicalTrials.gov Archive Site
Not Provided
  • Response rate
  • Progression-free survival
  • Overall survival
Not Provided
Not Provided
 
Biomarkers in Patients With Head and Neck Cancer
Detection of DNA Mutations in Head and Neck Squamous Cell Carcinoma

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.

OBJECTIVES:

  • To determine the mutation rates of HRAS and PIK3CA in patients with head and neck squamous cell carcinoma (HNSCC) who were treated with cisplatin/placebo and cisplatin/cetuximab on protocol ECOG-E5397.
  • To determine the association between HRAS or PIK3CA mutation status and clinical benefits (i.e., response, progression-free survival, and overall survival) in patients treated with cisplatin/cetuximab compared with those receiving cisplatin/placebo on protocol ECOG-E5397.

OUTLINE: DNA is isolated from one unstained slide per patient. The mutations in HRAS and PIK3CA are determined using BEAMING technology.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Samples submitted for research from patients participating in E5397
Head and Neck Cancer
  • Biological: cetuximab
  • Drug: cisplatin
  • Genetic: DNA analysis
  • Genetic: gene expression analysis
  • Genetic: mutation analysis
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
January 1, 2012
January 1, 2012   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Treated on protocol ECOG-E5397

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01466257
CDR0000715520
ECOG-E5397T2
Not Provided
Not Provided
Not Provided
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Principal Investigator: Christine H. Chung, MD Sidney Kimmel Comprehensive Cancer Center
Eastern Cooperative Oncology Group
May 2017